Latest news
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 - Business WireBusiness Wire · Fri, 07 Aug 2026 20:30:00 GMTAbCellera Reports Q2 2026 Business Results - Business WireBusiness Wire · Wed, 05 Aug 2026 20:05:00 GMTSara Coca Membribes: MDX2001 is a First-in-Human Multispectic T-Cell Engager in Solid Tumors - OncodailyOncodaily · Wed, 05 Aug 2026 19:07:53 GMTAbCellera Biologics (ABCL) Signs Vertex Deal, Is The Stock Still Cheap? - simplywall.stsimplywall.st · Sat, 01 Aug 2026 07:00:00 GMTVertex’s latest autoimmune TCE play involves $28M to AbCellera - Fierce BiotechFierce Biotech · Wed, 29 Jul 2026 12:20:42 GMTAbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions - Business WireBusiness Wire · Wed, 29 Jul 2026 07:00:00 GMTAbCellera expands multispecific T-cell engager licensing with USD 28m Vertex deal for autoimmune disease - allsci.comallsci.com · Wed, 29 Jul 2026 07:00:00 GMTAbCellera inks drug discovery deal with Vertex Pharma - Seeking AlphaSeeking Alpha · Wed, 29 Jul 2026 07:00:00 GMT